Gilead Sciences, Inc. (GILD) AI Stock Analysis

Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, focused on developing and commercializing treatments for unmet medical needs across the United States, Europe, and international markets. The company specializes in therapies for HIV/AIDS, with products including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. It also provides Veklury for COVID-19, therapies for liver diseases such as Epclusa, Harvoni, Vosevi, Vemlidy, and Viread, and treatments in hematology, oncology, and cell therapy including Yescarta, Tecartus, Trodelvy, and Zydelig.

Gilead increased annual revenue from $27.30B in FY2021 to $29.44B in FY2025, representing a 5-year revenue CAGR of 3.6%. Net income improved from $6.22B in FY2021 to $8.51B in FY2025, after dipping to $480.0M in FY2024. In FY2025, operating margin reached 39.7%, up from 5.8% in FY2024 and 36.3% in FY2021, while gross margin stood at 78.8%. R&D expense was $5.80B in FY2025. For the trailing twelve months, revenue reached $30.46B, but the profit margin was -10.6% and EPS was -$2.65. In the latest quarter ended June 30, 2026, quarterly revenue grew 10.2% year-over-year and quarterly earnings rose 54.8%.

As of June 30, 2026, Gilead held $3.18B in cash and short-term investments against total debt of $26.25B, resulting in net debt of $23.07B. Shareholders' equity stood at $11.83B, producing a debt-to-equity ratio of 2.22 and a current ratio of 1.27. In FY2025, the company generated $10.02B in operating cash flow and $9.46B in free cash flow. Capital expenditures were $563.0M, while cash allocation included $1.92B in share buybacks and $4.00B in dividends paid.

Gilead trades at a forward P/E of 15.6x, compared to 23.0x for the median of its Nasdaq-100 Healthcare peers. Its price-to-sales ratio is 6.4x, slightly below the peer median of 6.5x, while its EV-to-EBITDA stands at 117.8x versus the peer median of 20.9x. The stock has gained 35.8% over the past year and 176.0% over the past five years, outpacing the S&P 500 (SPY) returns of 16.8% and 83.0% over the same respective periods. The shares last closed at $156.19, which is 14.3% above their 200-day average.

Gilead offers a forward annual dividend of $3.28 per share, representing a 2.10% dividend yield and a payout ratio of 43.5%. The quarterly dividend has been paid for 12 consecutive years, delivering a 5-year annualized dividend growth rate of 3.0%. The most recent ex-dividend date was September 15, 2026.

Wall Street analysts hold 16 Strong Buy, 6 Buy, 5 Hold, and 1 Sell ratings on Gilead, with zero Strong Sell recommendations. The mean price target of $159.85 suggests a 2.3% upside from the last close of $156.19. Gilead beat EPS estimates in each of the last 4 quarters. For the fiscal year ending December 31, 2026, consensus estimates project EPS of -$0.40 on revenue of $30.73B, before recovering to an estimated EPS of $9.94 on revenue of $32.84B in the following year. The next earnings date is October 29, 2026.

This page is an AI-written research summary of Gilead Sciences, Inc. (GILD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GILD income statement, GILD balance sheet, GILD key metrics, GILD analyst forecast, GILD chart. See the GILD stock overview for the latest quote and news.